Chimerix, Inc.

NASDAQ:CMRX

3.47 (USD) • At close January 15, 2025
Bedrijfsnaam Chimerix, Inc.
Symbool CMRX
Munteenheid USD
Prijs 3.47
Beurswaarde 312,078,267
Dividendpercentage 0%
52-weken bereik 0.75 - 3.8
Industrie Biotechnology
Sector Healthcare
CEO Mr. Michael T. Andriole M.B.A.
Website https://www.chimerix.com

An error occurred while fetching data.

Over Chimerix, Inc.

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a

Vergelijkbare Aandelen

Biomea Fusion, Inc. logo

Biomea Fusion, Inc.

BMEA

4.06 USD

Longeveron Inc. logo

Longeveron Inc.

LGVN

1.75 USD

Harvard Bioscience, Inc. logo

Harvard Bioscience, Inc.

HBIO

1.98 USD

OptiNose, Inc. logo

OptiNose, Inc.

OPTN

6 USD

Inozyme Pharma, Inc. logo

Inozyme Pharma, Inc.

INZY

1.38 USD

High Tide Inc. logo

High Tide Inc.

HITI

3.12 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)